Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 111,378

Document Document Title
WO/2016/066755A2
The present invention refers to 4-amino-substituted pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives of formula I and IV able to target the Src family kinases (SFKs) such as Src, Fyn and Hck tyrosine kinases as well as ...  
WO/2016/066582A1
The present invention relates to method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solva...  
WO/2016/069801A1
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, ...  
WO/2016/069510A1
The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential trea...  
WO/2016/067297A1
The compositions and compounds of formula I, formula II, formula III and formula IV which includes a salt of valproic acid or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as ph...  
WO/2016/065481A1
There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stim...  
WO/2016/066700A1
The present invention is directed to alpha-MSH analogues for treatment of neurodegenerative disorders.  
WO/2016/070181A1
Cotinine, a natural product present in tobacco leaves that has antidepressant effects on locomotor activity and sensorimotor abilities, was tested on depressive-like behavior, neuroinflammation and neurogenesis. When administered to mice...  
WO/2016/069854A1
Provided herein are compositions containing the drug OSU-03012 (AR-12) in combination with one or more drugs selected from multi-kinase inhibitors, HDAC inhibitors, folate antimetabolites, DNA alkylating agents, and sphingosine- 1 -phosp...  
WO/2016/066755A3
The present invention refers to 4-amino-substituted pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives of formula I and IV able to target the Src family kinases (SFKs) such as Src, Fyn and Hck tyrosine kinases as well as ...  
WO/2016/069898A1
Disclosed herein are delivery systems including coated and uncoated yarns, yarn precursors, threads, fibers, and other substrates for the constant or near-constant release of active compounds, as well as methods for manufacturing such de...  
WO/2016/063253A1
A method to provide prognosis of RRMS is disclosed. In presence of Gal-8 autoantibodies in the patient's blood sample a poor prognosis is given. The disclosure also provides a tool for healthcare professionals to make decision of startin...  
WO/2016/064997A1
Provided are methods for treating fatigue or depression in a subject that has a neurodegenerative disease, such as multiple sclerosis, and/or treating a neurodegenerative disease patient (e.g., a multiple sclerosis patient) presenting wi...  
WO/2016/063297A1
The present invention relates to the alkylidene phosphonate esters of formula I wherein, R1 is selected from a group consisting of hydrogen or alkyl group; R2 is selected from a group consisting of hydrogen, hydroxy, alkyl, alkoxy, nitro...  
WO/2016/063985A1
The present invention provides a production method for neural cells or nerve tissue, the method including steps (1)-(3): (1) a first step for culturing pluripotent stem cells in the absence of feeder cells in a culture medium that includ...  
WO/2016/063303A1
The present invention relates to the N-substituted beta-carbolinium compounds of general formula A and formulae I and II wherein, R1 and R2 groups are selected from halogens or trifluoromethyl; R3 group is selected from hydrogen or methy...  
WO/2016/064774A1
A method of improving neurological function in a human subject includes identifying a human subject diagnosed with at least one of post-CNS trauma, post-concussion syndrome, a chronic refractive epileptic encephalopathic condition, autis...  
WO/2016/064987A1
The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a B...  
WO/2016/062239A1
A method for promoting neurite outgrowth is provided by the invention, and the method comprises exposing the neurons to an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof....  
WO/2016/063995A1
In the present invention, compound such as (lR,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-flu orophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be usef...  
WO/2016/062688A1
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, preferably BRD4-inhibiting carboxamides of general formula (I), in which R1, R2, R3, R4 and R5 have the meanings specified in the description,...  
WO/2016/064711A1
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need...  
WO/2016/063933A1
Provided is a heterocyclic compound that has an excellent RBP4 reducing effect and is useful as a preventive or therapeutic drug for diseases or symptoms mediated by a rise in RBP4 or by retinol supplied by RBP4. A compound represented b...  
WO/2016/062182A1
Disclosed is a pregabalin sustained-release preparation, wherein the sustained-release tablet consists of a pharmaceutically active ingredient containing pregabalin or a salt or hydrate thereof, a gel framework material containing algini...  
WO/2016/062860A1
The present invention relates to a pharmaceutical composition comprising amorphous vortioxetine hydrobromide, a process for the preparation thereof, use thereof and a method for stabilizing said pharmaceutical composition.  
WO/2016/064009A1
The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an...  
WO/2016/062746A1
The present invention relates to hydroxy-triglycerides, their synthesis, a pharmaceutical and/or nutraceutical composition which comprises at least one of said hydroxy- triglycerides, and a method which comprises the administration to a ...  
WO/2016/064932A1
The present invention relates to systems for brain stimulation during sleep and methods for increasing vividness of a subject's dreams or for directing the subject matter of a subject's dreams. The system comprises a brain stimulation mo...  
WO/2016/061801A1
Disclosed are a method and carrier for targeting amyloid protein based on polypeptides. The carrier is used to transport compounds or medicines through the blood brain barrier of an individual to be bound with amyloid protein in the brai...  
WO/2016/063296A1
The present invention relates to the polyprenylated phloroglucinol compounds of formulae I and II. The present invention also provides synthesis and p-glycoprotein induction activity of the alkyl- and acyl- polyprenylated phloroglucinol ...  
WO/2016/065019A1
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions...  
WO/2016/064914A1
The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opio...  
WO/2016/062737A1
A novel benzoimidazolyl compound, pharmaceutical compositions containing such a compound and its use in therapy.  
WO/2016/061632A1
The present invention provides an isolated or recombinant Fn14-binding protein comprising an antigen binding domain, wherein the antigen binding domain binds specifically to Fn14 or a cell expressing Fn14.  
WO/2016/065264A1
Provided herein are compounds of formula (I) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with Nrf2/ NF-κΒ pathways....  
WO/2016/062242A1
The present invention provides a peptide capable of promoting neuron growth, particularly a peptide capable of promoting neurite growth, and an application thereof.  
WO/2016/058192A1
A traditional Chinese medicine composition for treating insomnia, and a preparation method for same, the composition being composed of 45-55 parts by weight Radix paeoniae alba, 45-55 parts by weight Semen ziziphi spinosae, 45-55 parts b...  
WO/2016/058537A1
Uses of an achaete-scute complex homolog-like 1 (Ascl1) gene or a protein thereof or an accelerator thereof: (i) use in preparing a pharmaceutical composition for inducing astrocytes to become functional neuron cells; and/or (ii) use in ...  
WO/2016/059162A1
Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathe...  
WO/2016/060190A1
The present invention addresses the problem of providing a therapeutic agent for cognition disorders induced by amyloid β-protein, the therapeutic agent functioning by a mechanism in which amyloid β-protein is involved but which is dif...  
WO/2016/059403A1
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Len...  
WO/2016/059404A1
The present disclosure relatesto the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with im...  
WO/2016/059399A1
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impair...  
WO/2016/059307A1
The invention relates to a drug combination comprising gaseous xenon and at least one antagonist of the NMDA receptors in a liquid or solid form for treating a disease caused by a dysfunction of the dopaminergic synaptic transmission in ...  
WO/2016/058071A1
The present invention relates to the method for extracting and isolating active substances from umbu pulp (Spondias tuberosa Arr. Camara). Besides high acetylcholinesterase inhibitory activity, the active substances also exhibit powerful...  
WO/2016/061393A1
Monomethyl and monoethyl fumarate prodrugs, pharmaceutical compositions comprising the monomethyl and monoethyl fumarate prodrugs, and methods of using monomethyl and monoethyl fumarate prodrugs and pharmaceutical compositions for treati...  
WO/2016/059269A1
The invention relates to the methods for producing derivatives of 3-alkylamino-1H-indole acrylate (I) with transcription factor Nrf2-inducing activity, free radical scavenging activity and neuroprotective ability. The invention also rela...  
WO/2016/060111A1
The purpose of the present invention is to provide a method for producing γδT cells with which it is possible to obtain a cell population including a large amount of γδT cells and including virtually no cells infected by human T-cell...  
WO/2016/059412A1
This invention relates to novel compounds of formula (I) wherein 'A' is a 5 or 6 membered heteroaryl group, unsubstituted or substituted with 1, 2 or 3 groups as defined in claim 1; X is a bond or -(CRA1RB1)n-; Y is selected from: a bond...  
WO/2016/060122A1
An adhesive patch which is provided with a supporting body and an adhesive layer that is arranged on at least one surface of the supporting body. The adhesive layer contains at least one substance that is selected from the group consisti...  

Matches 251 - 300 out of 111,378